This site uses cookies to improve your browsing experience. By using this site, you agree to their use. Cookie Information

Let's collaborate Boehringer Ingelheim

HNSCC afatinib clinical trials

Afatinib* has been investigated in two Phase III trials in patients with head and neck squamous cell carcinoma (HNSCC) progressing on or after platinum-based therapy. The rationale for these studies is that there is no well-defined standard of care and few efficacious treatment options for patients in this setting.

You can find out more about the clinical trials of afatinib in this setting using the links below.

Filter by:
Show all trials

LUX-Head & Neck 1 trial

Phase III
3
published

Recurrent and/or metastatic HNSCC; second-line or later

Afatinib vs methotrexate

LUX-Head & Neck 1 trial
Patients who have been pre-treated with platinum-based chemotherapy (second-line)

LUX-Head & Neck 3

Phase III
3
reported

Study of afatinib vs methotrexate as second-line treatment in Asian patients with HNSCC

LUX-Head & Neck 3
Patients who have been pre-treated with platinum-based chemotherapy (second-line)

Related content

Preliminary data on afatinib plus pembrolizumab

Real-world study of the combination of afatinib plus pembrolizumab in patients with recurrent or metastatic HNSCC

Head and neck squamous cell carcinoma in focus

Our current understanding of the characteristic features and biology of HNSCC and the challenges in its clinical management
Back to top

*Afatinib is approved in more than 80 markets including the EU, Japan, Taiwan, and Canada under the brand name GIOTRIF®, in the US under the brand name GILOTRIF® and in India under the brand name Xovoltib®; for the full list please see here. Registration conditions differ internationally; please refer to locally approved prescribing information. Afatinib is being investigated in urothelial carcinoma (UC) and head and neck squamous cell carcinoma (HNSCC) and is not approved for these uses. The efficacy and safety of afatinib in UC and HNSCC have not been established.